Exenatide Presentation

Exenatide Use in diabetes OPD at the RD&E Clinical Audit Dr Pamela Bowman (FY2) Dr Angus Jones (ACF/ST3)

Background ,[object Object],[object Object],[object Object],[object Object],[object Object]

Exenatide ,[object Object],[object Object],[object Object],[object Object],[object Object]

Actions of Exenatide ,[object Object],[object Object],[object Object],[object Object],[object Object]

NICE guidelines 2008 Type 2 Diabetes Starting Exenatide ,[object Object],[object Object],[object Object],[object Object]

NICE guidelines 2008 Type 2 Diabetes Continuation of Exenatide ,[object Object],[object Object],[object Object]

Criteria ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Standards (1) ,[object Object],[object Object],[object Object],[object Object],[object Object]

Standards (2) ,[object Object],[object Object]

Standards (3) ,[object Object],[object Object],[object Object]

Methods Data Collection & Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Results (1) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Results (1) cont... ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Results (1) cont... ,[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],Results (2)

Results (3) ,[object Object],[object Object],[object Object],[object Object]

Results (3) cont..... ,[object Object],[object Object],[object Object],[object Object],[object Object]

Results (4) ,[object Object],[object Object],[object Object],[object Object],[object Object]

Results (4) cont.... ,[object Object],[object Object],[object Object],[object Object],[object Object]

Results (3&4) ,[object Object],[object Object],[object Object],[object Object]

Changes in weight (kg) over time

Exenatide stopped ,[object Object],[object Object],[object Object],[object Object],[object Object]

Reasons for stopping Exenatide

Doing particularly well on Exenatide ,[object Object],[object Object],[object Object],[object Object]

Conclusions (1) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Conclusions (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Discussion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Suggestions for change ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Future considerations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

References ,[object Object],[object Object],[object Object]

Exenatide Presentation

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Semelhante a Exenatide Presentation

Semelhante a Exenatide Presentation (20)

Mais de PeninsulaEndocrine

Mais de PeninsulaEndocrine (20)

Último

Último (20)

Exenatide Presentation